A passion for
patient care with


When treating both respiratory and non-respiratory disease, even dispersion of inhaled therapeutics throughout the lung is a critical factor driving efficacy and safety.

Comparison 1

Conventional dry powder technologies
rely on the use of lactose blending or
low-density particles to facilitate

Comparison 3

To optimize dispersion of therapeutic particles,
the scientists and engineers at PULMATRiX have
developed a technological innovation, iSPERSE.

iSPERSE makes possible a new generation of pulmonary-delivered
therapies to dramatically improve patient outcomes.

Our mission

PULMATRiX is committed to the development and commercialization of novel and transformational medicines for patients all over the world, using our proprietary iSPERSE technology to optimally deliver both respiratory and non-respiratory therapies via the respiratory system. Our initial focus is on respiratory diseases.

Learn about our pipeline


iSPERSE™ is a scalable platform, with application across drug classes and dry-powder delivery devices. This creates broad potential for pipeline development and strategic partnership.

  • Partnering with Cipla on the Pulmazole™ anti-fungal program in Allergic Bronchopulmonary Aspergillosis (ABPA)
  • Cipla is India’s 2nd largest pharmaceutical company with global presence in over 130 countries, over 35 manufacturing facilities, and a vast network for direct commercialization and strategic alliances
  • Our partnership validates the Pulmazole™ development plan and the potential of iSPERSE™
    Pulmazole™ (itraconazole formulated with iSperse™) provided about 5-fold higher lung exposure and 80-fold lower plasma exposure than Sporanox, the currently available oral formulation of itraconazole, at one tenth the dose.1 Pulmazole has the potential to address the underlying cause of disease and avoid the side effects of oral therapy

Learn more about Pulmazole™

  • Partnering with Johnson and Johnson for worldwide development and commercialization of PUR1800 as part of the J&J Lung Cancer Initiative
  • Johnson & Johnson is the world’s largest healthcare company with over 130,000 employees and 130 years of existence
  • Our partnership further validates iSPERSE™ and opens a global opportunity in lung cancer
    Data supports that PUR1800 engineered with iSperse™ has the ability to deliver 3x the effective lung dose versus the lactose blend formulation of the active ingredient while improving the safety margin

Learn more about PUR1800

  • Partnering with Nocion Therapeutics to explore new technologies to enable and improve inhaled drug delivery
  • Nocion Therapeutics is a biopharmaceutical company developing novel small molecule charged sodium channel blockers
  • Our partnership further validates the potential of iSPERSE™ to broadly benefit the development and reach of inhaled therapeutics
  • Partnering with Sensory Cloud to develop and commercialize a potential nasal prophylactic and anticontagion product for COVID-19
  • Sensory Cloud Inc., is a privately held company that specializes in the delivery of aerosolized products for over-the-counter (OTC) healthcare and wellbeing
  • This partnership leverages the origins of PULMATRiX as a biodefense company and its intellectual property to help combat rapidly emerging global pandemics

To inquire about partnering with PULMATRiX, e-mail us at bd@pulmatrix.com.



Small, dense, and dispersible particles for highly efficient delivery of respiratory and non-respiratory therapies via the respiratory system

Explore iSPERSE

References: 1. Agarwal R, Chakrabarti A, Shah A, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy. 2013;43(8):850-873.